The U.S. FDA approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.  Venclexta is manufactured by AbbVie Inc. of North Chicago, Illinois, and marketed by AbbVie and Genentech USA Inc. of South San Francisco, California.

According to the National Cancer Institute, CLL is one of the most common types of leukemia in adults, with approximately 15,000 new cases diagnosed each year. CLL is characterized by the progressive accumulation of abnormal lymphocytes, a type of white blood cell. Patients with CLL who have a 17p deletion lack a portion of the chromosome that acts to suppress cancer growth. This chromosomal abnormality occurs in approximately 10 percent of patients with untreated CLL and in approximately 20 percent of patients with relapsed CLL.

 

References:

  1. https://news.abbvie.com/news/abbvie-receives-fda-accelerated-approval-venclexta-venetoclax-tablets-first-bcl-2-inhibitor-in-relapsedrefractory-chronic-lymphocytic-leukemia-patients-with-17p-deletion.htm?icid=venetoclax-showcase
  2. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm